SUMMARY Serum phenytoin concentrations were monitored prospectively in 26 patients with previously untreated partial epilepsy, during monotherapy with phenytoin. Only six remained entirely seizure-free, although only four experienced further tonic-clonic seizures. There was no correlation between serum phenytoin concentrations and freedom from partial seizures in those patients in whom such seizures recurred. There did appear to be a correlation between serum phenytoin concentration and freedom from tonic-clonic seizures. 
Several authors have attempted to correlate serum phenytoin levels with clinical efficacy. ' In spite of a widespread belief to the contrary, a consistent therapeutic range has not been defined, although there is agreement that increasing serum phenytoin levels are generally associated with improved seizure control.
Two important factors might cause variation in a therapeutic range between patients; firstly, differences in the severity of epilepsy, and secondly, the nature of the seizure disorder. The second factor may be of particular importance in view of the poorer prognosis, and lesser responsiveness of partial seizures to anticonvulsant drugs compared to tonic-clonic seizures. 23 During a controlled randomised comparison of phenytoin and valproate4 we have been able to monitor serum phenytoin levels prospectively in adult patients with previously untreated partial epilepsy receiving monotherapy with phenytoin. We have explored the relationship between seizure control and plasma concentration of phenytoin by relating the occurrence of seizures during a three month period to plasma phenytoin concentration at the commencement of that period. Table 2 describes data from six patients remaining free of seizures throughout the follow up period, and 20 patients who experienced further seizures after commencing therapy. In those patients remaining seizure-free, serum phenytoin concentrations were consistently above 10 ,g/ml in three, consistently below 10 ug/ml in two, and variable in the final patient. Serum levels from these patients have been excluded from further analysis as it is impossible to compare seizure containing and seizure free periods for these patients.
Methods
In those 20 patients with further seizures during the study, serum concentrations of phenytoin were significantly higher in periods during which only partial seizures occurred than in seizure-free periods (p < 0-05)! This paradoxical finding may be explained by more therapy-resistant patients (receiving higher doses of phenytoin, with higher serum levels) contributing more periods to the group of seizure containing periods.
Serum levels of phenytoin were lowest in nine periods (from four patients) in which secondarily generalised fits occurred. The difference between mean phenytoin levels in such periods and those in fit free periods and periods containing only partial seizures was not statistically significant perhaps because of the small number of periods in which tonic-clonic seizures occurred.
We have further examined the relationship between plasma phenytoin concentration and seizure control by comparing mean values from those three month periods in which seizures occurred and those in which they did not, in all 16 patients with partial epilepsy in whom this was possible (fig). (Four patients with further seizures were excluded from this analysis because they had no observed periods which were seizure-free.) We again found a trend towards slightly higher plasma phenytoin levels in periods containing partial seizures only, compared to fit free periods. This difference was not however significant (Students paired t test, t = 0-39). However, serum phenytoin levels were significantly lower in periods containing secondarily generalised fits than in fit free periods (t = -3-25, p < 0.05).
If there is a clearly defined lower limit to the therapeutic range many patients in the figure should be represented by lines crossing such a lower limit in Turnbull, RawUns, Weightman, Chadwick "Therapeutic" serum concentration ofphenytoin a direction which passes upward from mean levels during periods containing seizures to mean levels in fit free periods. Such a test would not allow the definition of a lower limit of the therapeutic range at 10 ,ug/ml as no less then five lines cross such a limit in the wrong direction and only one crosses it in the correct direction. Using these criteria it might be possible to define a lower limit to the therapeutic range against secondarily generalis_d seizures at a lower level than that conventionally accepted, that is, at between 6 and 8 ug/ml. It was possible to compare the frequency of partial seizures in periods during which 10 patients had plasma levels firstly in the range of 0-9-9 ,ug/ml (mean frequency 1-53 seizures per month) and then in the range of 10-20 ,g/ml (mean frequency 2-87 seizures per month). Five patients had periods firstly in the range of 10-20 ug/ml (mean frequency seizures per month) and subsequently in periods with plasma levels greater than 20 ,tg/ml (mean frequency 2-7 seizures per month). These differences were not statistically significant.
Discussion
A therapeutic range for phenytoin of 10-20 ,ug/ml is widely accepted and used in clinical practice. However, the many studies which have attempted to define the relationship between serum concentrations of phenytoin and therapeutic effect are unsatisfactory.6 Often they are retrospective, and usually include patients whose epilepsy is resistant to drugs and who are receiving other anticonvulsants.7 '-0 Frequently they compare one group of patients with good seizures control, with a group of patients with poor seizure control;8-" too few studies have studied individual patients during long periods in which they have differing serum levels. '2 '3 Often the period of seizure control which is related to an individual serum level is not specified, '4 '5 and almost all information relates only to control of tonic-clonic seizures.
In spite of these problems, there is agreement that there is a wide variation in the therapeutic serum levels of phenytoin between individual patients,' and perhaps even within the same patient at differing times." The present study emphasises this variation, two patients being entirely seizure-free for prolonged periods with relatively low serum levels, possibly reflecting a mild underlying epilepsy.
If '5 An absence of correlation between plasma concentration of both carbamazepine, '6 and valproate '7 and control of partial seizures has previously been reported. It 
